Premium
Letter: are sorafenib‐related adverse events associated with prolonged survival? Authors' reply
Author(s) -
SanduzziZamparelli Marco,
Sapena Víctor,
Bruix Jordi,
Reig María
Publication year - 2020
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.15572
Subject(s) - medicine , sorafenib , adverse effect , intensive care medicine , oncology , hepatocellular carcinoma